EPTIFIBATIDE
Generic: EPTIFIBATIDE
Meitheal Pharmaceuticals Inc.Manufacturer
INTRAVENOUSRoute
EPTIFIBATIDEActive Substance
2024-05-09Original Approval
EPTIFIBATIDE is FDA application ANDA213599, sponsored by MEITHEAL. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class III2026-02-12
Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous ULabeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/
Class III2024-05-22
Eptifibatide injection 20mg/10mL (2mg/mL), 10mL Single-Dose Vial, Rx only, Mfd. In India for: AuroMedics Pharma, LLC, E.Failed Impurities/Degradation Specifications: failed related substance identified as Eptifibatide di
Top Reported Reactions
1
MYOCARDIAL INFARCTION
208 reports
2
THROMBOCYTOPENIA
65 reports
3
DRUG INEFFECTIVE
52 reports
4
HYPOTENSION
41 reports
5
HAEMOGLOBIN DECREASED
37 reports
6
ACUTE MYOCARDIAL INFARCTION
33 reports
7
HAEMORRHAGE
33 reports
8
CARDIAC ARREST
29 reports
9
VASCULAR STENT THROMBOSIS
28 reports
10
HAEMATOMA
26 reports